UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
April 1, 1999
ACCESS PHARMACEUTICALS, INC.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
DELAWARE
---------------------------------------------
(State of other jurisdiction of incorporation)
0-9314 83-0221517
- ------------------------ ---------------------------------
(Commission File Number) (IRS Employer Identification No.)
2600 Stemmons Freeway, Suite 176, Dallas, Texas 75207
- ----------------------------------------------- ----------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code:
---------------------------------------------------
(214) 905-5100
N/A
------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
<PAGE>
Item 5. Other Events
Access Pharmaceuticals, Inc. announced that it has entered into an agreement
to acquire Virologix Corporation ("Virologix"), a private company focused on
the development of product candidates for the prevention and treatment of
viral diseases including HIV. Under terms of the acquisition agreement the
Virologix shareholders will receive an undisclosed amount of Access Common
Stock. It is anticipated that the closing of the acquisition will take place
within the next 60 days. The transaction has been approved by the Boards of
Directors of both companies and the closing is subject to the approval of the
Virologix's shareholders, the completion of a private placement by Access and
other customary closing conditions.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Company has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
ACCESS PHARMACEUTICALS, INC.
By: /s/ Kerry P. Gray
------------------------
Title: President and CEO
Dated: April 1, 1999
